Yi Yan

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

A Randomized Clinical Study Comparing Double Kissing Crush With Provisional Stenting for Treatment of Coronary Bifurcation Lesions

Strategies and challenges for the next generation of antibody–drug conjugates

An Immunosuppressive Antibody–Drug Conjugate

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Artificial intelligence in cancer imaging: Clinical challenges and applications

Role of NKG2D and its ligands in cancer immunotherapy.

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

Matrix metallopeptidase 2 (MMP2) media la eliminación de MHC class I polypeptide-related sequence A (MICA) en el cáncer de células renales

Matrix metallopeptidase 2 (MMP2) mediates MHC class I polypeptide-related sequence A (MICA) shedding in renal cell carcinoma

[DK crush technique: modified treatment of bifurcation lesions in coronary artery].

Rational Design of CXCR4 Specific Antibodies with Elongated CDRs